Hyperscale Data (GPUS) shares rallied after the company said Monday that preliminary Q1 revenue exceeded $25 million.
Shares soared over 400% as intraday trading volume grew to over 253 million from a daily average of about 90,000.
Immutep (IMMP) said Monday that a phase 2b trial evaluating eftilagimod alfa in combination with Merck's (MRK) Keytruda as first line therapy in head and neck cancer patients produced an "excellent" median overall survival result of 17.6 months.
Shares soared 38% as intraday trading volume surged to over 5.51 million from a daily average of roughly 72,000.
BioCryst Pharmaceuticals (BCRX) shares jumped 15% following better-than-expected Q1 results.
Trading volume was more than 16 million, against a daily average of about 3.69 million.
Price: 7.15, Change: +5.78, Percent Change: +421.90
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。